Drugs / Mycophenolic Acid (MPA) (Myfortic®)
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02213068 Background | Jul 2014 → Sep 2020 | Epstein-Barr virus infection | Lorenzo Gallon | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mycophenolic Acid (MPA) (Myfortic) | “Mycophenolic Acid (MPA) (Myfortic®)” NCT02213068 ↗ |
| Known as | MPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02213068 ↗ |
| Route | Oral | “MPA: dosed orally per package insert beginning on the day of transplantation.” NCT02213068 ↗ |